Webinar Date/Time: Thu, Feb 8, 2024 11:00 AM EST
Achieve higher productivity in cell line optimization. Learn how a streamlined middle-down mass spectrometry workflow can improve molecular knowledge in less steps.
In biotherapeutic development, changing cell culture conditions is necessary to enable simpler, faster and more cost-effective drug delivery to patients. These changes, however, can induce cellular stress and adversely impact product quality, creating additional challenges in manufacturing.
Reliable and streamlined workflows to characterize post-translational modifications (PTMs) are necessary to create a comprehensive molecular profile of a biopharmaceutical. Adopting workflows that provide these critical pieces of information with minimal processing steps allows for less labor intensive characterization of PTMs and reduces the risk of introducing artificial PTMs or other undesirable modifications.
Key Learning Objectives:
Who Should Attend:
Director, Analytical Sciences
J&J Innovative Medicine
Hirsh Nanda is the Director of Analytical Sciences at Johnson & Johnson Innovative Medicines. Hirsh joined J&J in 2015. In his current role, he leads an Analytical Sciences group supporting research and development of biologic therapeutics, including cell line engineering and development. His team performs in-depth mass spectroscopy and biophysical characterization across modalities and next-generation therapies.